Multicentre audit of the use of drotrecogin alfa (activated) in UK critical care units

被引：0
|
作者：
K Rowan
C Welch
E North
D Harrison
机构：
[1] Intensive Care National Audit & Research Centre,
[2] ,undefined
来源：
Critical Care | / 11卷 / Suppl 2期
关键词：
Severe Sepsis; Organ Dysfunction; Hospital Mortality; Data Collection Form; Critical Care Unit;
D O I：
10.1186/cc5216
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey
    Guido Bertolini
    Carlotta Rossi
    Abramo Anghileri
    Sergio Livigni
    Antonio Addis
    Daniele Poole
    [J]. Intensive Care Medicine, 2007, 33 : 426 - 434
  • [2] Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey
    Bertolini, Guido
    Rossi, Carlotta
    Anghileri, Abramo
    Livigni, Sergio
    Addis, Antonio
    Poole, Daniele
    [J]. INTENSIVE CARE MEDICINE, 2007, 33 (03) : 426 - 434
  • [3] Drotrecogin alfa (activated): real-life use and outcomes for the UK
    Rowan, Kathryn M.
    Welch, Catherine A.
    North, Emma
    Harrison, David A.
    [J]. CRITICAL CARE, 2008, 12 (02):
  • [4] Drotrecogin alfa (activated): real-life use and outcomes for the UK
    Kathryn M Rowan
    Catherine A Welch
    Emma North
    David A Harrison
    [J]. Critical Care, 12
  • [5] Audit of adherence to National Institute of Clinical Excellence guidelines for the use of drotrecogin alfa (activated)
    R Vedantham
    B Iyowu
    [J]. Critical Care, 11 (Suppl 2):
  • [6] A large, single-centre UK registry of drotrecogin alfa-activated use
    L Macchiavello
    G Ellis
    S Bowden
    M Smithies
    [J]. Critical Care, 11 (Suppl 2):
  • [7] A registry of patients treated with drotrecogin alfa (activated) in belgian intensive care units - An observational study
    Vincent, J. -L.
    Laterre, P. -F.
    Decruyenaere, J.
    Spapen, H.
    Raemaekers, J.
    Damas, F.
    Rogiers, P.
    Sartral, M.
    Haentjens, T.
    Nelson, D.
    Janes, J.
    [J]. ACTA CLINICA BELGICA, 2008, 63 (01) : 25 - 30
  • [8] Use of national guidelines for the introduction of Drotrecogin alfa (activated)
    S Mackenzie
    L Patterson
    L Plenderleith
    F MacKirdy
    [J]. Critical Care, 8 (Suppl 1):
  • [9] Current issues regarding the use of drotrecogin alfa (activated)
    Hassan, E
    Mann, HJ
    [J]. PHARMACOTHERAPY, 2002, 22 (12): : 206S - 215S
  • [10] Use of drotrecogin alfa (activated) for severe sepsis in New Jersey acute care hospitals
    Dombrovskiy, Viktor
    Martin, Andrew
    Sunderram, Jagadeeshan
    Paz, Harold
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 (12) : 1151 - 1156
12345